What do systematic reviews say?

Nicotinamide plus tetracycline vs prednisone

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Clobetasol propionate cream vs prednisone

The review found no eligible studies for this question.

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Clobetasol propionate cream vs prednisone

Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).

• Interventions for bullous pemphigoid 2023 · Cochrane Headline outcomes only
  RR 0.65 [0.5, 0.86]
  1 study · 341 participants
  Low

Swallowed fluticasone vs prednisone

It is very uncertain whether swallowed fluticasone changes clinical improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.09 [0.9, 1.33]
  1 study · 80 participants
  Very low

Swallowed fluticasone vs prednisone

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Swallowed fluticasone vs prednisone

It is very uncertain whether swallowed fluticasone changes histological improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.1 [0.87, 1.38]
  1 study · 80 participants
  Very low

Swallowed fluticasone vs prednisone

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Very low

Swallowed fluticasone vs prednisone

It is very uncertain whether swallowed fluticasone changes endoscopic improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 1.13 [0.91, 1.41]
  1 study · 80 participants
  Very low

Swallowed fluticasone vs prednisone

The review found no eligible studies for this question.

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Swallowed fluticasone vs prednisone

It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).

• Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
  RR 0.5 [0.16, 1.53]
  1 study · 80 participants
  Very low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.06 [0.61, 1.87]
  2 studies · 84 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.01 [0.43, 2.37]
  2 studies · 63 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.88 [0.53, 1.45]
  1 study · 53 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.88 [0.53, 1.45]
  1 study · 53 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.59 [0.87, 2.88]
  1 study · 60 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 1.07 [0.19, 5.95]
  1 study · 60 participants
  Low

Oral cyclophosphamide vs prednisone or placebo

It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).

• Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
  RR 0.71 [0.05, 10.89]
  1 study · 60 participants
  Very low

Weekend‐only vs prednisone

• Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 57 participants
  Moderate

Weekend‐only vs prednisone

• Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Low
• Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 57 participants
  Moderate

Weekend‐only vs prednisone

• Corticosteroids for the treatment of Duchenne muscular dystrophy 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Moderate